therapeutic parasite reduction or removal of harmful materials · asfa guideline: rationale for...

47
Therapeutic Parasite Reduction or Removal of Harmful Materials Yanyun Wu, MD, PhD Chief Medical Officer

Upload: others

Post on 21-Sep-2020

4 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Therapeutic Parasite Reduction or Removal of Harmful Materials

Yanyun Wu, MD, PhD

Chief Medical Officer

Page 2: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Conflict of Interest

• None

Page 4: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically
Page 5: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Cases Case 1

A 53-year-old male resident of Connecticut was admitted to ER in July. He recently had a week-long camping trip.

He presented with high fevers (40 C), shaking chill, weakness, and fatigue. He had severe hemolytic anemia (Hct of 21%)/pancytopenia (platelet count of 33K), with signs of disseminated intravascular coagulation, acute renal failure, and respiratory failure. He was intubated and transferred to ICU overnight.

There was no history of splenectomy or immunodeficiency.

Page 6: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Cases Case 2 • 60 year old woman with a prolonged hospital stay

(7 months) due to multiple medical and surgical issues.

• For the last week, patient has been spiking temp of 39 to 40 C.

• Significant DAT negative hemolytic anemia (Hct of 27%)

• She received transfusion of 4 units RBC 4 weeks ago. And she has a history of splenectomy

Page 8: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

N Engl J Med 2012;366:2397-407.

Page 9: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Human babesiosis summary

Causative pathogen: protozoal parasite in phylum Apicomplexa

Target tissue: red blood cells

Transmission:

Ixodid ticks (Ixodes scapularis)

Blood transfusion

Perinatal/transplacental

Diagnosis: epidemiology, symptoms, microscopy, PCR, antibody

Treatment: atovaquone/azithromycin or clindamycin/quinine, exchange transfusion

Courtesy of Dr. Peter Krause, Yale

Page 10: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesia species causing human infection

US

• B. microti

• B. duncani

• B. divergens-like

Vannier and Krause, N. Engl. J. Med., 2012

Courtesy of Dr. Peter Krause, Yale

Europe • B. divergens • B. venatorum • B. microti

Asia • B. microti-like • K01

Page 11: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Year

Nu

mb

er c

ases

Babesiosis in the US 1986-2011

0

100

200

300

400

500

600

700

800

900

1000

1100

86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11

Courtesy of Dr. Peter Krause, Yale

One of the most common infections of free-living animals worldwide and an emerging infection in humans

Page 12: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Human babesiosis

• Require both a competent vertebrate and nonvertebrate host to maintain transmission cycles

• Transmitted by ixodid ticks to their vertebrate hosts

• Replicate in the vertebrate hosts’ red blood cells

Page 13: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Vannier E and Krause PJ. New Engl J Med, 2012

Transmission of Babesia microti by the Ixodes scapularis Tick

Courtesy of Dr. Peter Krause, Yale

Page 14: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Trophozoite

Merozoite

Pre-gametocyte

Gametes fuse

in the gut

Zygote enters

gut epithelium

Sporoblasts/Sporozoites

in salivary glands

Life cycle of Babesia microti

Courtesy of Dr. Peter Krause, Yale

Page 15: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Life cycle of Babesia microti

Page 16: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Page 17: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis clinical manifestations

1. Asymptomatic infection 2. Viral-like illness Fever, chills, sweats, headache, fatigue 3. Severe illness and death (5-21%) >50, asplenic, HIV, malignancy, blood transfusion recipients • Persistent, relapsing illness HIV/AIDS, malignancy, asplenic, immunosuppressive drugs • The incubation period is usually 1–3 weeks

Courtesy of Dr. Peter Krause, Yale

Page 18: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis: persistent parasitemia

(DNA)

Krause, Spielman, Telford, et al., New Engl J Med, 1998

Courtesy of Dr. Peter Krause, Yale

Page 19: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Transfusion transmitted babesiosis

• Symptoms delayed as long as 1 week to 6 months after transfusion

• Symptoms similar to those of tick-transmitted disease but often more severe because blood recipients are often immunocompromised

• Mortality rate ranges from about 10% to 21%

Courtesy of Dr. Peter Krause, Yale

Page 20: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis in highly immunocompromised patients

Clinical characteristic Cases

(n=14)

Controls

(n=46)

P value

Median number of antibiotic courses

(range)

4 (2-10) 1 <0.001

Median number hospital admissions

(range)

1.5 (0-4) 1 (0-1) <0.001

Median weeks of therapy (range) 13 (4-

102)

1 (0.5-1.5) <0.001

Number with complications (percent) 8 (57) 2 (4) <0.001

Number with fatal infection (percent) 3 (21) 0 <0.02

Krause, Gewurz, Hill, et al. Clin Inf Dis, 2008

Courtesy of Dr. Peter Krause, Yale

Page 21: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis in highly immunocompromised patients • People suffering from broad-based immunosuppression are at risk of persistent relapsing Babesia microti infection

• Adaptive immunity (B and T cell) are important for resolution of infection

• These patients generally require anti-babesial therapy for at least 6 weeks, including 2 weeks after babesia are no longer detected on blood smear

Courtesy of Dr. Peter Krause, Yale

Page 22: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

General approach to diagnosis

Epidemiology

Medical history

Physical examination

Laboratory testing

Courtesy of Dr. Peter Krause, Yale

Page 23: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Specific laboratory diagnosis

Microbial detection

Blood smear

Polymerase chain reaction

Small rodent inoculation

Antibody detection

IFA

Immunoblot

ELISA

Courtesy of Dr. Peter Krause, Yale

Page 24: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Diagnostic algorithm for babesiosis

Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9

Page 25: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Diagnosis

Cunha et al, Clinical Infectious Diseases® 2015;60(5):827–9

Page 26: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Treatment of babesiosis caused by Babesia microti

Mild illness Atovaquone (PO) + azithromycin (PO) Administration for 7-10 days

Severe illness Clindamycin (IV or PO) + quinine (PO) Administration for 7-10 days

Persistent or relapsing illness Atovaquone (PO) + azithromycin (PO) OR Clindamycin (IV or PO) + quinine (PO) Administration for at least 6 wks, including 2 wks after parasites are no longer detected on blood smear

Courtesy of Dr. Peter Krause, Yale

Page 27: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Page 28: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

• What are we removing?

• What are we adding back?

• Have we changed patient outcome?

• Give me the proof!

• Show me the data!

Page 29: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Readings: 1. Dorman et al, TRANSFUSION Volume 40, March 2000 2. Spaete et al, Journal of Clinical Apheresis 24:97–105 (2009)

Page 30: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Dorman et al, TRANSFUSION Volume 40, March 2000

Page 31: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Dorman et al, TRANSFUSION Volume 40, March 2000

Page 32: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Dorman et al, TRANSFUSION Volume 40, March 2000

Page 33: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Dorman et al, TRANSFUSION Volume 40, March 2000

Page 34: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Dorman et al, TRANSFUSION Volume 40, March 2000

Page 35: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Summary

• 15 males (63%)

• The mean age: 56 years (SD 16; range, 25–77)

• The mean pretransfusion hemoglobin: 8.1 g/dl (SD 2.5; range, 4.7–13.7).

• The mean preRCE or preWBE level of parasitemia was 18% (SD 14; range, 1.6–60)

• The mean postExchange level of parasitemia was 3.6% (SD 3.8; range, 0.1–13.8) with a median of 2%

• Fifteen (63%) of the 24 patients were asplenic

• Two of four who died were asplenic, and a third was reported to have necrotic splenic lesions on postmortem exam

Page 36: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Spaete J et al, J Clin Apher. 2009;24(3):97-105.

Page 37: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Page 38: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Harmful Materials:

• Parasite: from RBC only?

• Cytokine?

• Free Heme

• Others?

Page 39: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

ASFA guideline: Rationale for therapeutic apheresis

1. First, it helps to lower the level of parasitemia by physically removing the infected RBCs from the blood stream and replacing them with noninfected RBCs. Because babesia organisms do not have an exo-erthrocytic phase, removal of RBC-associated parasites might be very effective.

2. Second, by removal of rigid infected cells, RBC exchange could decrease obstruction in the microcirculation and tissue hypoxia caused by adherence of RBCs to vascular endothelium.

3. Finally, the hemolytic process produces vasoactive compounds, including a variety of cytokines (including INF-g, TNF-a, IL-1, IL-6), nitric oxide and thromboplastin substances, which can promote renal failure and DIC. RBC exchange may help to remove the proinflammatory cytokines.

Page 40: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Shaio MF et al. Am J Trop Med Hyg. (1998)

Page 41: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

Shaio MF et al. Am J Trop Med Hyg. (1998)

Page 42: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Krause PJ, et al. Trends in Parasitology, 2007;23:605-610.

Courtesy of Dr. Peter Krause, Yale

Page 43: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Pathogenesis

Excessive erythrocyte cytoadherence: Additionally, erythrocytes infected with some babesia species

undergo membrane changes that cause these erythrocytes to adhere to the vascular endothelium Excessive pro-inflammatory cytokine production During a babesia infection, inflammatory cytokines including tumor

necrosis factor a (TNF-a) and interleukin 6, and adhesion molecules such as Eselectin, intracellular adhesion molecule 1 and vascular-cell adhesion molecule 1 are upregulated

While moderate synthesis of these factors may be protective,

excessive upregulation may result in severe babesiosis

Krause PJ, Daily J, Telford SR, et al. Trends Parasitol, 2007

Sloan et al, Journal of Clinical Apheresis 00:00–00 (2014)

Page 44: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

• Cytoadherence most thoroughly studied in B. bovis infection

• Cattle infected by B. bovis die from encephalopathy as erythrocytes obstruct brain blood vessels.

• B. bovis encephalopathy similar to human P. falciparum cerebral malaria

• Cytoadherence is beneficial for the parasite as it delays or prevents filtering/removal of infected RBCs by the spleen.

Erythrocyte cytoadherence

Courtesy of Dr. Peter Krause, Yale

Page 45: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Pro-inflammatory cytokines

• Severe disease occurs without erythrocyte cytoadherence for B. microti, suggesting other pathogenic mechanisms.

• Pro-inflammatory cytokines such as TNF-α and IFN-γ protect the host against B. microti infection but if produced in excess may cause severe symptoms and complications.

Courtesy of Dr. Peter Krause, Yale

Page 46: Therapeutic Parasite Reduction or Removal of Harmful Materials · ASFA guideline: Rationale for therapeutic apheresis 1. First, it helps to lower the level of parasitemia by physically

Babesiosis

• When do you start or stop?

• How to exchange?

• Patient consent?

• Others?